Summary
The treatment of human disease with tissue engineering constructs has tremendous potential and is an area of active research. However, the development of optimal combinations of matrices, cells, and growth factors/genes will require careful assessment of both preclinical as well as human clinical trials Evaluation of human clinical trials will be markedly improved by the development of noninvasive methods designed to directly assess the performance of the engineered construct. Adaptation and development of imaging methods will enhance evaluation, and will play a central role in clinical trials, as evidenced by the role of imaging in the ongoing trial examining the effect of Enbrel on periprosthetic bone loss.
This is a preview of subscription content, log in via an institution.
Buying options
Tax calculation will be finalised at checkout
Purchases are for personal use only
Learn about institutional subscriptionsPreview
Unable to display preview. Download preview PDF.
References
Antoniou J, Huk O, Zuko RD, Eyre D, Alini M. 2000. Collagen crosslinked N-telopeptides as markers for evaluating particulate osteolysis: a preliminary study. J. Orthop. Res. 18:64–67.
Arnoczky S. 1999. Building a meniscus. Biologic considerations. Clin. Orthop. 367:S244–253.
Athanasiou KA, Zhu C, Lanctot DR, Agrawal CM, Wang X. 2000. Fundamentals of biomechanics in tissue engineering of bone. Tissue Eng. 6:361–381.
Boardman DL, Dorey F, Thomas BJ, Lieberman JR. 2000. The accuracy of assessing total hip arthroplasty outcomes: a prospective correlation study of walking ability and 2 validated measurement devices. J. Arthrop. 15:200–204.
Carragee EJ. 1997. Single-level posterolateral arthrodesis, with or without posterior decompression, for the treatment of isthmic spondylolisthesis in adults. A prospective, randomized study. J. Bone Joint Surg. 79:1175–1180.
Childs LM, Goater JJ, O’Keefe RJ, Schwarz EM. 2001. Efficacy of Etanercept for wear debrisinduced osteolysis. J. Bone Miner Res. 16:338–47.
Christie MJ, DeBoer DK, Trick LW, Brothers JC, Jones RE, Vise GT, Gruen TA. 1999. Primary total hip arthroplasty with use of the modular S-ROM prosthesis. Four to seven-year clinical and radiographic results. J. Bone Joint Surg. 81:1707–1716.
Emerson RHJ, Sanders SB, Head WC, Higgins L. 1999. Effect of circumferential plasma-spray porous coating on the rate of femoral osteolysis after total hip arthroplasty. J. Bone Joint Surg. 81:1291–1298.
Grande DA, Breitbart AS, Mason J, Paulino C, Laser J, Schwartz RE. 1999. Cartilage tissue engineering: current limitations and solutions. Clin. Orthop. 367:S176–185.
Holzer G, Majeska RJ, Lundy MW, Hartke JR, Einhorn TA. 1999. Parathyroid hormone enhances fracture healing. A preliminary report. Clin. Orthop. 366:258–263.
Hoshino T, Muranishi H, Saito K, Notoya K, Makino H, Nagai H, Sohda T, Ogawa Y. 2000. Enhancement of fracture repair in rats with streptozotocin-induced diabetes by a single injection of biodegradable microcapsules containing a bone formation stimulant, TAK-778. J. Biomed Mater Res. 51:299–306.
Kanayama M, Cunningham BW, Sefter JC, Goldstein JA, Stewart G, Kaneda K, McAfee PC. 1999. Does spinal instrumentation influence the healing process of posterolateral spinal fusion? An in vivo animal model. Spine 24:1058–1065.
Lanza RP, Cooper DK. 1998. Xenotransplantation of cells and tissues: application to a range of diseases, from diabetes to Alzheimer’s. Mol. Med. Today 4:39–45.
Li R, Williams S, White M, Rein D. 1999. Dose control with cell lines used for encapsulated cell therapy. Tissue Eng. 5:453–466.
Plancher KD, Steadman JR, Briggs KK, Hutton KS. 1998. Reconstruction of the anterior cruciate ligament in patients who are at least forty years old. A long-term follow-up and outcome study. J. Bone Joint Surg. 80A:184–197.
Schwarz EM, Benz EB, Lu AP, Goater JJ, Mollano AV, Rosier RN, Puzas JE, O’Keefe RJ. 2000a. A quantitative small animal surrogate to evaluate drug efficacy in preventing wear debris-induced osteolysis. J. Orthop. Res. 18:849–855.
Schwarz EM, Looney RJ, O’Keefe RJ. 2000b. Anti-TNFa therapy as a clinical intervention for periprosthetic osteolysis. Arthritis Res. 2:165–168.
Slavkin HC, Panagis JS, Kousvelari E. 1999. Future opportunities for bioengineering research at the National Institutes of Health. Clin. Orthop. 367:S17–30.
van der Heijde DM. 2000. Radiographic imaging: the “gold standard” for assessment of disease progression in rheumatoid arthritis. Rheumatology 39:9–16.
Wright JC, Weinstein MC. 1998. Gains in life expectancy from medical interventions—standardizing data on outcomes. N. Engl. J. Med. 339:380–386.
Wright JG, Young NL, Waddell JP. 2000. The reliability and validity of the self-reported patient-specific index for total hip arthroplasty. J. Bone Joint Surg. 82:829–837.
Ziesche R, Hofbauer E, Wittmann K, Petkov V, Block LH. 1999. A preliminary study of long-term treatment with interferon gamma-1b and low-dose prednisolone in patients with idiopathic pulmonary fibrosis. N. Engl. J. Med. 341:1264–1269.
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2003 Springer-Verlag New York, Inc.
About this chapter
Cite this chapter
O’Keefe, R.J. et al. (2003). Assessment of the Performance of Engineered Tissues in Humans Requires the Development of Highly Sensitive and Quantitative Noninvasive Outcome Measures. In: Guilak, F., Butler, D.L., Goldstein, S.A., Mooney, D.J. (eds) Functional Tissue Engineering. Springer, New York, NY. https://doi.org/10.1007/0-387-21547-6_20
Download citation
DOI: https://doi.org/10.1007/0-387-21547-6_20
Publisher Name: Springer, New York, NY
Print ISBN: 978-0-387-95553-7
Online ISBN: 978-0-387-21547-1
eBook Packages: Springer Book Archive